Stock Forecast

  Standard BioTools Inc. ( FLDM) Stock. Should you Buy or Sell?    $ 3.71

-0.28 (-8.16 %)

Standard BioTools Inc. Analysis

Updated on 10-09-2022
Symbol FLDM
Price $3.71
Beta 1.138
Volume Avg. $956.99 thousand
Market Cap $286.41 M
52 Week Range $2.67 - $7.51

Standard BioTools Inc. opened the day at $3.71 which is -8.16 % on yesterday's close. Standard BioTools Inc. has a 52 week high of $7.51 and 52 week low of $2.67, which is a difference of $4.84. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $286.41 M and total net profit is $130581000 which means the company is trading at 2.19 times profit to market capitalization. Theoretically, if you were to buy Standard BioTools Inc. for $286.41 M, it would take 15 years to get your money back. Standard BioTools Inc. are in the Diagnostics & Research space which will have a sweet spot and industry standard for net profit multiples.

Price Chart

1 D | All


Fluidigm Corporation Stock Forecast - Is Fluidigm Corporation a Buy or Sell?

DCF ScoreStrong Buy
ROE ScoreStrong Sell
ROA ScoreSell
DE ScoreStrong Buy
PE ScoreSell
PB ScoreStrong Buy
Overall RecommendationBuy

Growth and Value

PE Ratio -2.449
Dividend Yiel 0.000
Net Profit Margin -0.939

Valuing Fluidigm Corporation

Price Book Value Ratio 12.924 Price To Book Ratio 12.924
Price To Sales Ratio 2.299 Price Earnings Ratio -2.449

How liquid is Fluidigm Corporation

Current Ratio 1.552
Quick Ratio 0.963


Debt Ratio 0.919 Debt Equity Ratio 11.298
Long Term Debt To Capitalization 0.861 Total Debt To Capitalization 0.864

Latest news about Standard BioTools Inc.

Fluidigm Corporation: Investment Opportunity

Fluidigm Corporation: Investment Opportunity

Date : 26/01/2022

Casdin Capital, Viking Global Investors Inject $250M In Fluidigm

Fluidigm Corporation (NASDAQ: FLDM) has approved a $250 million investment by Casdin Capital LLC and Viking Global Investors LP with zero-coupon convertible preferred shares with a conversion price of $3.40/share. The investment will significantly advance the Company's mission through new organic and inorganic growth initiatives while optimizing its cost structure.

Date : 24/01/2022

Fluidigm Shares Gain As Preliminary Q4, FY21 Sales Exceed Expectations

Fluidigm Corp (NASDAQ: FLDM) expects Q4 FY21 sales of $38.0 million - $38.3 million, exceeding the company's prior guidance of $31 million – $34 million and the analyst estimate of $32.7 million. Base product and service revenue, excluding COVID-19 testing, is expected to be $35.1 million - $35.4 million, +13%–14% Y/Y.

Date : 11/01/2022

Hot Penny Stocks To Buy Now? 4 To Add To Your List Today

Are these on your list of penny stocks to watch today? The post Hot Penny Stocks To Buy Now?

Date : 12/11/2021

Fluidigm Q3 Sales Trail Estimates; Cuts Annual Guidance As COVID-19 Sales Retreat

Fluidigm Corp (NASDAQ: FLDM) posted Q3 revenues of $28.5 million, down 29% Y/Y, missing the consensus of $30.00 million, citing supply chain issues affecting product fulfillment. Fluidigm is undertaking a review of various options to maximize shareholder value, including strategic alternatives, cost & capital structure, and operations and supply chain.

Date : 09/11/2021

About Standard BioTools Inc.

CEO : Mr. Stephen Linthwaite
Sector : Healthcare
Industry : Diagnostics & Research

Website :

Exchange : NASDAQ Global Select

Description :

Fluidigm Corporation creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Fluidigm Corporation has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

My Newsletter

Sign Up For Updates & Newsletters